Comparative clinical-related outcomes of Chinese patent medicines for cardiac hypertrophy: A systematic review and network meta-analysis of randomized clinical trials

Background: Persistent pathological cardiac hypertrophy has been associated with increased risk of heart failure and even sudden death. Multiple Chinese patent medicines (CPMs) have gained attention as alternative and complementary remedies due to their high efficiency and few side effects. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tianqi, Xu, Haoyang, Zhen, Dong, Fu, Danni, Zhao, Ming, Wei, Chengxi, Bai, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900025/
https://www.ncbi.nlm.nih.gov/pubmed/36755943
http://dx.doi.org/10.3389/fphar.2023.963099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900025/
https://www.ncbi.nlm.nih.gov/pubmed/36755943
http://dx.doi.org/10.3389/fphar.2023.963099

Ejemplares similares